Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for PTGX

Stock NameProtagonist Therapeutics Inc
TickerPTGX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS74366E1029

Show aggregate PTGX holdings

News associated with PTGX

Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by Barclays
Barclays began coverage on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $72.00 price target on the stock. Several other research firms have also issued reports on PTGX. JMP Securities increased their target price on […] - 2025-09-19 02:36:48
HC Wainwright Reiterates Buy Rating for Protagonist Therapeutics (NASDAQ:PTGX)
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $80.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 28.74% from the stock’s previous close. A number of other […] - 2025-09-19 02:36:47
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded at Leerink Partnrs
Leerink Partnrs upgraded shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) to a strong-buy rating in a research report released on Friday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Protagonist Therapeutics’ Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.61) EPS and FY2025 earnings at ($1.95) EPS. A number of other analysts […] - 2025-09-15 02:47:57
We Did The Math IJR Can Go To $133
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-28 09:18:11
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Mutual of America Capital Management LLC
Mutual of America Capital Management LLC decreased its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 3.9% during the 1st quarter, Holdings Channel.com reports. The firm owned 8,679 shares of the company’s stock after selling 348 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Protagonist Therapeutics were […] - 2025-08-13 05:45:10
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of “Buy” by Analysts
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been given a consensus recommendation of “Buy” by the nine research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation […] - 2025-08-08 04:42:56
Jefferies Financial Group Inc. Sells 857,602 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Jefferies Financial Group Inc. lessened its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 57.6% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 631,893 shares of the company’s stock after selling 857,602 shares during the period. Jefferies Financial Group Inc.’s holdings in Protagonist Therapeutics were worth $30,558,000 as of […] - 2025-08-01 05:38:53
Royce & Associates LP Buys New Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Royce & Associates LP bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 12,255 shares of the company’s stock, valued at approximately $593,000. A number of other hedge funds […] - 2025-07-30 04:49:05
XSMO's Underlying Holdings Could Mean 15% Gain Potential
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-28 08:27:31
Dinesh V. Ph D. Patel Sells 12,859 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) CEO Dinesh V. Ph D. Patel sold 12,859 shares of the company’s stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $54.86, for a total value of $705,444.74. Following the sale, the chief executive officer owned 570,603 shares in […] - 2025-07-25 06:28:57
Dinesh V. Ph D. Patel Sells 17,520 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) CEO Dinesh V. Ph D. Patel sold 17,520 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $54.79, for a total transaction of $959,920.80. Following the transaction, the chief executive officer owned 531,018 shares in the […] - 2025-07-25 05:42:54
Massachusetts Financial Services Co. MA Sells 723 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Massachusetts Financial Services Co. MA trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 2.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,726 shares of the company’s stock after selling 723 shares […] - 2025-07-21 05:51:00
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Holdings Lowered by Teacher Retirement System of Texas
Teacher Retirement System of Texas trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 8.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,025 shares of the company’s stock after selling 1,074 shares during the period. Teacher Retirement System […] - 2025-07-16 04:34:43
Amalgamated Bank Sells 467 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Amalgamated Bank cut its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 2.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,938 shares of the company’s stock after selling 467 shares during the quarter. Amalgamated Bank’s holdings […] - 2025-07-10 05:10:51
GAMMA Investing LLC Has $58,000 Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
GAMMA Investing LLC grew its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 153.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,203 shares of the company’s stock after buying an additional 728 shares during the period. GAMMA Investing […] - 2025-07-10 04:14:49
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of “Buy” from Analysts
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been assigned a consensus recommendation of “Buy” from the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the […] - 2025-07-09 04:43:49
Oregon Public Employees Retirement Fund Has $663,000 Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Oregon Public Employees Retirement Fund cut its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 2.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 13,700 shares of the company’s stock after selling 300 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in […] - 2025-07-08 05:24:51
Illinois Municipal Retirement Fund Sells 14,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Illinois Municipal Retirement Fund cut its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 41.8% in the 1st quarter, Holdings Channel.com reports. The fund owned 19,509 shares of the company’s stock after selling 14,000 shares during the period. Illinois Municipal Retirement Fund’s holdings in Protagonist Therapeutics were worth $943,000 as of […] - 2025-07-02 05:28:54
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by California State Teachers Retirement System
California State Teachers Retirement System cut its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 0.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 42,349 shares of the company’s stock after selling 316 shares during the quarter. California State Teachers Retirement System’s holdings in Protagonist Therapeutics were worth […] - 2025-06-09 05:00:56
Tidal Investments LLC Decreases Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Tidal Investments LLC trimmed its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 4.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 21,012 shares of the company’s stock after selling 1,050 shares during the period. Tidal Investments LLC’s holdings in Protagonist Therapeutics were worth $811,000 at the end of the most […] - 2025-05-27 05:22:57
Brokerages Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $65.44
Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) have been given an average recommendation of “Buy” by the nine research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to […] - 2025-05-23 03:14:53
Protagonist Therapeutics (NASDAQ:PTGX) Earns “Buy” Rating from HC Wainwright
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $80.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 71.64% from the stock’s previous close. Other equities research analysts […] - 2025-05-21 03:03:18
Deutsche Bank AG Acquires 17,763 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Deutsche Bank AG increased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 14.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 137,932 shares of the company’s stock after purchasing an additional 17,763 shares during […] - 2025-05-19 05:10:57
Comerica Bank Trims Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Comerica Bank decreased its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 1.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 20,558 shares of the company’s stock after selling 346 shares during the period. Comerica Bank’s holdings in Protagonist Therapeutics were worth $794,000 at the end of the most […] - 2025-05-14 05:20:53
Marshall Wace LLP Lowers Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Marshall Wace LLP trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 93.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,716 shares of the company’s stock after selling 295,657 shares during the quarter. […] - 2025-05-02 05:30:50
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Mariner LLC
Mariner LLC increased its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 12.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 17,983 shares of the company’s stock after buying an additional 2,004 shares during the period. Mariner LLC’s holdings in Protagonist Therapeutics were worth […] - 2025-04-30 05:19:01
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $65.44
Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) have earned a consensus recommendation of “Buy” from the nine research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation […] - 2025-04-28 02:22:54
Barclays PLC Decreases Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Barclays PLC reduced its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 0.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 126,733 shares of the company’s stock after selling 262 shares during the period. Barclays PLC’s holdings in Protagonist Therapeutics were worth $4,891,000 as of its most recent SEC filing. A […] - 2025-04-27 05:24:54
Bank of Montreal Can Boosts Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Bank of Montreal Can grew its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 4.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 6,250 shares of the company’s stock after acquiring an additional 270 shares during the quarter. Bank of Montreal Can’s holdings in Protagonist Therapeutics were worth $241,000 […] - 2025-04-25 04:36:55
Geode Capital Management LLC Acquires 2,366 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Geode Capital Management LLC raised its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 0.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,377,063 shares of the company’s stock after purchasing an additional 2,366 shares during the quarter. […] - 2025-04-14 05:00:52

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc PTGX holdings

DateNumber of PTGX Shares HeldBase Market Value of PTGX SharesLocal Market Value of PTGX SharesChange in PTGX Shares HeldChange in PTGX Base ValueCurrent Price per PTGX Share HeldPrevious Price per PTGX Share Held
2025-11-12 (Wednesday)22,066PTGX holding decreased by -73USD 1,872,300PTGX holding decreased by -21913USD 1,872,300-73USD -21,913 USD 84.85 USD 85.56
2025-11-11 (Tuesday)22,139USD 1,894,213PTGX holding increased by 51584USD 1,894,2130USD 51,584 USD 85.56 USD 83.23
2025-11-10 (Monday)22,139USD 1,842,629PTGX holding increased by 81693USD 1,842,6290USD 81,693 USD 83.23 USD 79.54
2025-11-07 (Friday)22,139USD 1,760,936PTGX holding decreased by -5313USD 1,760,9360USD -5,313 USD 79.54 USD 79.78
2025-11-06 (Thursday)22,139PTGX holding decreased by -73USD 1,766,249PTGX holding increased by 36378USD 1,766,249-73USD 36,378 USD 79.78 USD 77.88
2025-11-05 (Wednesday)22,212PTGX holding decreased by -730USD 1,729,871PTGX holding decreased by -25192USD 1,729,871-730USD -25,192 USD 77.88 USD 76.5
2025-11-04 (Tuesday)22,942PTGX holding decreased by -146USD 1,755,063PTGX holding increased by 1529USD 1,755,063-146USD 1,529 USD 76.5 USD 75.95
2025-11-03 (Monday)23,088PTGX holding decreased by -146USD 1,753,534PTGX holding decreased by -73123USD 1,753,534-146USD -73,123 USD 75.95 USD 78.62
2025-10-31 (Friday)23,234USD 1,826,657PTGX holding increased by 17890USD 1,826,6570USD 17,890 USD 78.62 USD 77.85
2025-10-30 (Thursday)23,234USD 1,808,767PTGX holding increased by 26952USD 1,808,7670USD 26,952 USD 77.85 USD 76.69
2025-10-29 (Wednesday)23,234USD 1,781,815PTGX holding decreased by -42286USD 1,781,8150USD -42,286 USD 76.69 USD 78.51
2025-10-28 (Tuesday)23,234PTGX holding increased by 219USD 1,824,101PTGX holding increased by 92222USD 1,824,101219USD 92,222 USD 78.51 USD 75.25
2025-10-27 (Monday)23,015USD 1,731,879PTGX holding increased by 8976USD 1,731,8790USD 8,976 USD 75.25 USD 74.86
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of PTGX by Blackrock for IE00B3VWM098

Show aggregate share trades of PTGX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-12SELL-73 84.850* 50.40 Profit of 3,679 on sale
2025-11-06SELL-7379.92077.000 77.292USD -5,642 49.74 Loss of -2,011 on sale
2025-11-05SELL-73078.12075.640 75.888USD -55,398 49.59 Loss of -19,194 on sale
2025-11-04SELL-14678.01075.440 75.697USD -11,052 49.45 Loss of -3,832 on sale
2025-11-03SELL-14680.43075.535 76.025USD -11,100 49.31 Loss of -3,900 on sale
2025-10-28BUY21978.51078.780 78.753USD 17,247 48.69
2025-10-24SELL-7374.86075.525 75.459USD -5,508 48.41 Loss of -1,975 on sale
2025-10-15BUY43877.68078.150 78.103USD 34,209 47.32
2025-10-02BUY7364.98065.500 65.448USD 4,778 47.12
2025-09-30BUY14666.43067.040 66.979USD 9,779 46.91
2025-08-21SELL-8156.04056.470 56.427USD -4,571 46.44 Loss of -809 on sale
2025-07-31BUY24053.86055.290 55.147USD 13,235 46.34
2025-06-30SELL-16255.27057.235 57.039USD -9,240 45.42 Loss of -1,883 on sale
2025-06-25SELL-8154.44054.955 54.904USD -4,447 45.21 Loss of -785 on sale
2025-06-20SELL-16253.34054.970 54.807USD -8,879 45.04 Loss of -1,583 on sale
2025-05-30BUY3,72847.47047.740 47.713USD 177,874 43.99
2025-05-23BUY6745.66045.990 45.957USD 3,079 43.90
2025-05-19SELL-6745.57045.580 45.579USD -3,054 43.83 Loss of -117 on sale
2025-05-15SELL-20144.41044.760 44.725USD -8,990 43.82 Loss of -183 on sale
2025-05-12SELL-6745.27045.830 45.774USD -3,067 43.80 Loss of -132 on sale
2025-05-09SELL-6742.97045.430 45.184USD -3,027 43.81 Loss of -92 on sale
2025-04-30SELL-6745.82046.015 45.995USD -3,082 43.78 Loss of -149 on sale
2025-04-24SELL-13444.85046.060 45.939USD -6,156 43.73 Loss of -295 on sale
2025-04-17SELL-6746.28046.870 46.811USD -3,136 43.61 Loss of -214 on sale
2025-04-15SELL-20146.95048.320 48.183USD -9,685 43.55 Loss of -931 on sale
2025-04-14SELL-20145.03045.510 45.462USD -9,138 43.53 Loss of -388 on sale
2025-04-09SELL-26842.57043.910 43.776USD -11,732 43.58 Loss of -51 on sale
2025-04-07SELL-46943.21045.320 45.109USD -21,156 43.61 Loss of -702 on sale
2025-04-04SELL-67044.44046.450 46.249USD -30,987 43.60 Loss of -1,774 on sale
2025-03-31BUY6748.36048.800 48.756USD 3,267 43.45
2025-03-19SELL-13454.35054.540 54.521USD -7,306 42.58 Loss of -1,600 on sale
2025-03-14SELL-40254.78055.390 55.329USD -22,242 42.10 Loss of -5,319 on sale
2025-03-13SELL-13454.90058.700 58.320USD -7,815 41.91 Loss of -2,198 on sale
2025-03-12SELL-2,27857.65060.600 60.305USD -137,375 41.69 Loss of -42,414 on sale
2025-03-07SELL-13438.35039.900 39.745USD -5,326 41.25 Profit of 201 on sale
2025-03-06SELL-20139.05039.400 39.365USD -7,912 41.28 Profit of 385 on sale
2025-03-03SELL-6738.50042.510 42.109USD -2,821 41.41 Loss of -47 on sale
2025-02-28SELL-5,52237.59037.660 37.653USD -207,920 41.48 Profit of 21,109 on sale
2025-02-26SELL-8136.15036.250 36.240USD -2,935 41.65 Profit of 438 on sale
2025-02-25SELL-24335.09036.820 36.647USD -8,905 41.77 Profit of 1,244 on sale
2025-02-18BUY40537.75039.100 38.965USD 15,781 42.13
2025-02-13BUY8138.68038.720 38.716USD 3,136 42.34
2025-02-12BUY8137.42037.540 37.528USD 3,040 42.44
2025-02-11BUY24336.99038.010 37.908USD 9,212 42.55
2025-02-06BUY72937.75039.310 39.154USD 28,543 42.84
2025-01-27BUY8138.36039.890 39.737USD 3,219 43.87
2024-12-30BUY40538.51038.850 38.816USD 15,720 44.55
2024-12-06BUY32442.06042.765 42.694USD 13,833 44.86
2024-12-05BUY8141.68043.050 42.913USD 3,476 44.97
2024-12-04BUY40540.58042.180 42.020USD 17,018 45.13
2024-11-29BUY40543.80045.258 45.112USD 18,270 45.42
2024-11-27BUY32444.95045.600 45.535USD 14,753 45.46
2024-11-26BUY8144.83046.515 46.346USD 3,754 45.48
2024-11-21BUY40541.65043.380 43.207USD 17,499 45.63
2024-11-20BUY24340.65041.180 41.127USD 9,994 45.91
2024-11-18BUY97240.39041.050 40.984USD 39,836 46.71
2024-11-12BUY64843.17046.640 46.293USD 29,998 46.94
2024-11-08BUY40546.23048.860 48.597USD 19,682 46.99
2024-11-07BUY1,21547.61048.690 48.582USD 59,027 46.95
2024-11-06BUY16247.60048.670 48.563USD 7,867 46.89
2024-10-31BUY8145.84047.320 47.172USD 3,821 47.18
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of PTGX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19204,1012,581524,51238.9%
2025-09-18261,238603538,96748.5%
2025-09-17160,871455278,66257.7%
2025-09-16119,487213179,49166.6%
2025-09-15164,48190265,27562.0%
2025-09-12129,2771,000230,32856.1%
2025-09-11242,7640391,63862.0%
2025-09-10158,6691,425254,84662.3%
2025-09-09425,476500622,21868.4%
2025-09-08528,123800611,36386.4%
2025-09-05518,63311,824804,83964.4%
2025-09-04337,3852,916576,29258.5%
2025-09-03195,5701,053372,18252.5%
2025-09-02188,3990271,34869.4%
2025-08-29165,571500265,84062.3%
2025-08-28272,112902423,84764.2%
2025-08-27322,27411,729514,92562.6%
2025-08-2667,7973206,57332.8%
2025-08-25108,1181,807147,92673.1%
2025-08-2292,5800136,50467.8%
2025-08-2167,903732226,49030.0%
2025-08-20137,7474,436275,16950.1%
2025-08-19108,5912,229172,54662.9%
2025-08-18145,06689190,75276.0%
2025-08-15102,8631,000136,93775.1%
2025-08-14166,2630194,33785.6%
2025-08-13142,9894,887265,97853.8%
2025-08-12119,6661,400138,81286.2%
2025-08-11161,8090224,27072.1%
2025-08-08126,345380200,06163.2%
2025-08-07250,92610327,01476.7%
2025-08-06118,632274136,88586.7%
2025-08-0595,3525128,07174.5%
2025-08-04107,6633,147140,66576.5%
2025-08-01102,6430185,38255.4%
2025-07-31134,67426,403236,09357.0%
2025-07-3088,9861,477128,49769.3%
2025-07-29108,417242253,16542.8%
2025-07-28195,26419241,34780.9%
2025-07-25117,334156198,47059.1%
2025-07-24191,250125255,62474.8%
2025-07-23393,78353542,67272.6%
2025-07-22117,37920,048158,45174.1%
2025-07-2192,24593135,80967.9%
2025-07-1893,30898145,56464.1%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.